Actively Recruiting
Assessment of Stroke and Systemic Embolism Prevention with REGN7508 Compared to Apixaban in Adults with Atrial Fibrillation
Led by Regeneron Pharmaceuticals · Updated on 2026-10-26
15364
Participants Needed
54
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an experimental drug called REGN7508, a monoclonal antibody against Factor XI, compared to apixaban in adults with atrial fibrillation, a condition where the heart beats too fast and irregularly. The study aims to assess the safety and effectiveness of REGN7508 in preventing stroke and systemic embolism. Other aspects include monitoring side effects and whether the body produces antibodies against REGN7508. Participants will be randomly assigned to receive either REGN7508 plus placebo or apixaban plus placebo. Both treatments are given according to the study protocol. This Phase 3, double-blind trial includes two groups running in parallel. The study spans approximately 36 months, during which participants take the assigned treatment and are regularly monitored. During the trial, participants will attend scheduled visits for assessments including monitoring for strokes, systemic embolism, bleeding events, and adverse reactions. Researchers will also check for the presence and levels of anti-drug antibodies against REGN7508. The primary outcomes focus on the time to first stroke or systemic embolism and bleeding events over about three years. Safety and effectiveness will be closely observed throughout the study duration.
CONDITIONS
Brief Title
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here